Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: MG data of dilution

PROVIDER: PRJNA1264748 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR33619755_1.fastq.gz	Fastqsanger.gz
	SRR33619755_2.fastq.gz	Fastqsanger.gz
	SRR33619756_1.fastq.gz	Fastqsanger.gz
	SRR33619756_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 51

Similar Datasets

Project description:Progressive dilution data

| PRJNA1260745 | ENA

Project description:Dilution to extinction_bacterial data

| PRJNA849396 | ENA

Project description:MT data of dilution

| PRJNA1265293 | ENA

IRF4-dependent division-coupled reprogramming events [IRF4cKO.ATACseq]

Project description:To assess the timing and scope of IRF4–dependent reprogramming in vivo, CTV-labeled IRF4–sufficient and –deficient B cells were transferred into mMT hosts. One day later, hosts were challenged with 50 mg LPS. Three days post-LPS challenge, transferred cells were recovered and sorted from divisions 0, 1, 3, 4, 5, and 6 as determined by CTV dilution for ATAC–seq.

2021-07-30 | GSE173435 | GEO

IRF4-dependent division-coupled reprogramming events [IRF4cKO.RNAseq]

2021-07-30 | GSE173436 | GEO

Salmonella growth condition adaptation

Project description:To determine the impact of a low Mg(2+)/pH defined growth medium (MgM) on the proteome of Salmonella enterica serotype Typhimurium, researchers cultured S. Typhimurium cells in the medium under two different conditions termed MgM Shock and MgM Dilution and then comparatively analyzed the bacterial cells harvested from these conditions by a global proteomic approach.

2013-10-07 | PXD000392 | Pride

Comparative transcriptional analysis of Desulfovibrio alaskensis G20 grown under various syntrophic and fermentative conditions on pyruvate relative to respiratory growth

Project description:Pyruvate fermentation pathway and energetics of Desulfovibrio alaskensis strain G20 under syntrophic coculture and fermentative monoculture conditions Expression data for Desulfovibrio alaskensis strain G20 grown in chemostats on pyruvate under respiratory conditions (sulfate-limited and pyruvate-limited monoculture, dilution rate 0.047 and 0.027 h-1), fermentative conditions (monoculture, dilution rate 0.036 h-1), and syntrophic conditions (coculture with Methanococcus maripaludis or Methanospirillum hungatei, dilution rate of 0.047 and 0.027 h-1)

2013-12-12 | GSE53226 | GEO

dynamic SILAC CGR8 mESC DMSO/CHX

Project description:mESCs were cultured at least 2 weeks in medium medium: N2B27 for SILAC (DMEM/F12 for SILAC (AthenaES), Neurobasal for SILAC (AthenaES), Sodium Pyruvate (40 mg/mL), N2 (1X), B27 (0.5X), Pen/Strep (1%), L-glutamine (2 mM), beta-mercaptoethanol (50 µM)) + 2i/LIF supplemented with (medium) 13C6 15N4 L-arginine (0.65 mM), (medium) 13C6 L-arginine (0.55 mM), and L-Proline (200 mg/L)84. Before switching from light to heavy medium, cells were treated with 0.05 µg/mL CHX or equivalent dilution of DMSO in 6-well plates. We treated the cells with 0.05 µg/mL CHX. At timepoint 0 h, we replaced medium medium with pre-warmed heavy medium: N2B27 for SILAC (Thermo scientific) supplemented with (heavy) 13C6 15N2 L-Lysine-2HCl (0.65 mM), (heavy) 13C6 15N4 L-Arginine-HCl (0.55 mM), and L-Proline (200 mg/L) for mESC.

2025-10-07 | PXD061306 | Pride

dynamic SILAC NIH/3T3 treated with DMSO/CHX

Project description:NIH/3T3 cells were cultured at least 2 weeks in light medium: DMEM for SILAC (Thermo scientific) supplemented with PS, dialyzed FBS (Thermo scientific), (light) L-Lysine-2HCl (0.666 mM), (light) L-Arginine-HCl (0.399 mM)44, and L-Proline (200 mg/L). Before switching from light to heavy medium, cells were treated with 0.05 µg/mL CHX or equivalent dilution of DMSO in 6-well plates. At timepoint 0 h, we replaced light medium with pre-warmed heavy medium: DMEM for SILAC (Thermo scientific) supplemented with PS, dialyzed FBS (Thermo scientific), (heavy) 13C6 15N2 L-Lysine-2HCl (0.666 mM), (heavy) 13C6 15N4 L-Arginine-HCl (0.399 mM), and L-Proline (200 mg/L) for NIH/3T3.

2025-10-07 | PXD061384 | Pride

GV1001 combination therapy in metastatic colorectal cancer

Project description:Interventions: Drug : Study design &Intervention schedule This study is a multicenter, phase 2, single arm study. Individual investigators are allowed to choose 2nd line chemotherapy agents,bevacizumab, cetuximab,aflibercept depending on their decision. GVl001 is injected intradermally on days 1, 3, 5 and 8 of the first cycle of 2nd line chemotherapy with a dose of 0.56 mg, and then injected on day 1 of subsequent chemotherapy. GV1001 should be injected intradermally in the lower abdomen with 0.2 mL of diluted to 0.30 mL of 0.9% normal saline (2.8 mg/mL), administered immediately after dilution (at least within 6 hours after dilution). This treatment is repeated every 2 weeks until the discontinuation of treatment due to the patients’ request, the toxicity, or the progress of the disease. Primary outcome(s): Disease control rate

| 2511784 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data